Su Wenhua, Huo Qian, Wu Hao, Wang Lulin, Ding Xiaoxue, Liang Liwen, Zhou Liang, Zhao Yan, Dan Juhua, Zhang Hong
Faculty of Life Science and Biotechnology, Kunming University of Science and Technology, 650500, Kunming, People's Republic of China.
Department of Cardiology, The First People's Hospital of Yunnan Province, 650032, Kunming, People's Republic of China.
Cell Biosci. 2021 Aug 3;11(1):153. doi: 10.1186/s13578-021-00668-4.
Cardiac hypertrophy, characterized by the enlargement of cardiomyocytes, is initially an adaptive response to physiological and pathological stimuli. Decompensated cardiac hypertrophy is related to fibrosis, inflammatory cytokine, maladaptive remodeling, and heart failure. Although pathological myocardial hypertrophy is the main cause of hypertrophy-related morbidity and mortality, our understanding of its mechanism is still poor. Long noncoding RNAs (lncRNAs) are noncoding RNAs that regulate various physiological and pathological processes through multiple molecular mechanisms. Recently, accumulating evidence has indicated that lncRNA-H19 is a potent regulator of the progression of cardiac hypertrophy. For the first time, this review summarizes the current studies about the role of lncRNA-H19 in cardiac hypertrophy, including its pathophysiological processes and underlying pathological mechanism, including calcium regulation, fibrosis, apoptosis, angiogenesis, inflammation, and methylation. The context within which lncRNA-H19 might be developed as a target for cardiac hypertrophy treatment is then discussed to gain better insight into the possible biological functions of lncRNA-H19 in cardiac hypertrophy.
心肌肥大的特征是心肌细胞增大，最初是对生理和病理刺激的一种适应性反应。失代偿性心肌肥大与纤维化、炎性细胞因子、适应性不良重塑和心力衰竭有关。尽管病理性心肌肥大是肥大相关发病率和死亡率的主要原因，但我们对其机制的了解仍然很少。长链非编码RNA（lncRNA）是一类通过多种分子机制调节各种生理和病理过程的非编码RNA。最近，越来越多的证据表明lncRNA-H19是心肌肥大进展的有效调节因子。本综述首次总结了目前关于lncRNA-H19在心肌肥大中作用的研究，包括其病理生理过程和潜在的病理机制，包括钙调节、纤维化、凋亡、血管生成、炎症和甲基化。然后讨论了lncRNA-H19可能作为心肌肥大治疗靶点的背景，以便更好地了解lncRNA-H19在心肌肥大中可能的生物学功能。
